Details
Biosimilars for Cancer Treatment
A Promising Approach|
213,99 € |
|
| Verlag: | Springer |
| Format: | |
| Veröffentl.: | 01.07.2024 |
| ISBN/EAN: | 9789819730018 |
| Sprache: | englisch |
| Anzahl Seiten: | 300 |
Dieses eBook enthält ein Wasserzeichen.
Beschreibungen
<p>The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers.</p>
<p>It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments.</p>
<p>This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment.</p>
<p>It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments.</p>
<p>This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment.</p>
<p>1. An Overview of Biosimilars.- 2. Immunobiology of Cancer.- 3. Mechanism of Biosimilars for the treatment of Cancer.- 4. Biosimilars in Colorectal Cancer.- 5. Biosimilars in Cervical Caner.- 6. Biosimilars in Prostate Cancer.- 7. Biosimilars in Gastric Cancer.- 8. Biosimilars in Lung Cancer.- 9. A Recent Overview of The Growing Applications of Biosimilars in Pancreatic Cancer Management- Current Picture and Future Perspectives.- 10. Biosimilars in Breast Cancer.- 11. Biosimilars in Hepatocellular Carcinoma.- 12. Biosimilars in Ovarian Cancer.- 13. Biosimilars in Blood Cancer.- 14. Biosimilars in Clinical Trials.- 15. Regulatory Considerations of Biosimilars in Cancer.- 16. Future Scope of Biosimilars for the Treatment of Various Cancers.</p>
<p>Dr. Shvetank Bhatt is currently working as an associate professor in the school of health sciences and technology, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra, India. He has done M.Pharm in pharmacology from Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka, India and Ph.D. in neuropharmacology from Birla Institute of Technology and Science (BITS) Pilani, Pilani Campus, Rajasthan, India. His areas of specialization are CNS disorders, pain, inflammation and immuno oncology. He has published numerous papers. He is a life member of the Association of Pharmaceutical Teachers of India (APTI) and the Indian Pharmacological Society (IPS).</p>
<p> </p>
<p>Dr. Harish Dureja is head of the department of pharmaceutical sciences, Maharshi Dayanand University, Rohtak, Haryana, India, and Director of the Centre for IPR Studies and Professional Consultancy Cell at M. D. University, Rohtak, India. He earned his master’s in pharmacy from Punjabi University,Patiala, India, and Ph.D. in pharmaceutical sciences from Maharshi Dayanand University, Rohtak, India. He has published numerous articles in journals of repute. Dr. Dureja is also actively engaged in committees of various central and state universities, namely the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Pharmacy Council of India (PCI), All India Council of Technical Education (AICTE), National Testing Agency (NTA) and National Assessment and Accreditation Council (NAAC), etc.</p>
<p> </p>
<p>Dr. Samir Gunvantbhai Patel works as dean, faculty of pharmacy, professor, pharmaceutical chemistry and analysis, at Ramanbhai Patel College of Pharmacy (RPCP), Gujarat, India. He has more than 18 years of academic experience. His major research areas are design, synthesis and biological evaluation of cyclic peptides and synthetic derivatives for treating breast cancer, colon cancer and cancer metastasis. He has published several research articles and a few book chapters.</p>
<p> </p>
<p>Dr. Archita Samir Patel is an assistant professor, pharmaceutical chemistry and analysis, Ramanbhai Patel College of Pharmacy (RPCP), Gujarat, India. She has more than 18 years of academic experience. Her major research areas are the analysis of small molecules, development and validation of stability indicating analytical methods for small molecules and herbal actives, impurity profiling of synthetic drug substances and developing analytical methods using a chemometrics approach. She has published several research articles and a few book chapters.</p>
<p> </p>
<p>Dr. Kamal Dua is a senior lecturer in the discipline of pharmacy at the graduate school of health, University of Technology Sydney (UTS), Australia. He has research experience of over 13 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a node leader of drug delivery research in the centre for inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua's research in two complementary areas; drug delivery and immunology are evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published numerous research articles in journals of repute and authored and co-authored a few books. He is also an active member of many national and international professional societies.</p>
<p> </p>
<p>Dr. Harish Dureja is head of the department of pharmaceutical sciences, Maharshi Dayanand University, Rohtak, Haryana, India, and Director of the Centre for IPR Studies and Professional Consultancy Cell at M. D. University, Rohtak, India. He earned his master’s in pharmacy from Punjabi University,Patiala, India, and Ph.D. in pharmaceutical sciences from Maharshi Dayanand University, Rohtak, India. He has published numerous articles in journals of repute. Dr. Dureja is also actively engaged in committees of various central and state universities, namely the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Pharmacy Council of India (PCI), All India Council of Technical Education (AICTE), National Testing Agency (NTA) and National Assessment and Accreditation Council (NAAC), etc.</p>
<p> </p>
<p>Dr. Samir Gunvantbhai Patel works as dean, faculty of pharmacy, professor, pharmaceutical chemistry and analysis, at Ramanbhai Patel College of Pharmacy (RPCP), Gujarat, India. He has more than 18 years of academic experience. His major research areas are design, synthesis and biological evaluation of cyclic peptides and synthetic derivatives for treating breast cancer, colon cancer and cancer metastasis. He has published several research articles and a few book chapters.</p>
<p> </p>
<p>Dr. Archita Samir Patel is an assistant professor, pharmaceutical chemistry and analysis, Ramanbhai Patel College of Pharmacy (RPCP), Gujarat, India. She has more than 18 years of academic experience. Her major research areas are the analysis of small molecules, development and validation of stability indicating analytical methods for small molecules and herbal actives, impurity profiling of synthetic drug substances and developing analytical methods using a chemometrics approach. She has published several research articles and a few book chapters.</p>
<p> </p>
<p>Dr. Kamal Dua is a senior lecturer in the discipline of pharmacy at the graduate school of health, University of Technology Sydney (UTS), Australia. He has research experience of over 13 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a node leader of drug delivery research in the centre for inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua's research in two complementary areas; drug delivery and immunology are evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published numerous research articles in journals of repute and authored and co-authored a few books. He is also an active member of many national and international professional societies.</p>
<p>The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers.</p>
<p>It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments.</p>
<p>This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment.</p>
<p>It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments.</p>
<p>This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment.</p>
Covers the recent clinical trials of biosimilars for cancer treatment Provides information about the analysis of regulatory complexities in cancer care Explores the role of biosimilars in improving the overall survival rate and quality of life of the patient
Diese Produkte könnten Sie auch interessieren:
